Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19.
<h4>Objectives</h4>The development of a prognostic mortality risk model for hospitalized COVID-19 patients may facilitate patient treatment planning, comparisons of therapeutic strategies, and public health preparations.<h4>Methods</h4>We retrospectively reviewed the electron...
Main Authors: | Donald A Berry, Andrew Ip, Brett E Lewis, Scott M Berry, Nicholas S Berry, Mary MrKulic, Virginia Gadalla, Burcu Sat, Kristen Wright, Michelle Serna, Rashmi Unawane, Katerina Trpeski, Michael Koropsak, Puneet Kaur, Zachary Sica, Andrew McConnell, Urszula Bednarz, Michael Marafelias, Andre H Goy, Andrew L Pecora, Ihor S Sawczuk, Stuart L Goldberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0255228 |
Similar Items
-
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
by: Andrew Ip, et al.
Published: (2020-01-01) -
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
by: Andrew Ip, et al.
Published: (2021-01-01) -
New business development in a diversified technological corporation
by: Berry, Charles Andrew
Published: (2005) -
A savanna response to precipitation intensity.
by: Ryan S Berry, et al.
Published: (2017-01-01) -
Ukraine and singular optics
by: Berry Michael
Published: (2023-02-01)